U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H14ClN3O4S3
Molecular Weight 383.895
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Althiazide, (S)-

SMILES

NS(=O)(=O)C1=C(Cl)C=C2N[C@H](CSCC=C)NS(=O)(=O)C2=C1

InChI

InChIKey=VGLGVJVUHYTIIU-NSHDSACASA-N
InChI=1S/C11H14ClN3O4S3/c1-2-3-20-6-11-14-8-4-7(12)9(21(13,16)17)5-10(8)22(18,19)15-11/h2,4-5,11,14-15H,1,3,6H2,(H2,13,16,17)/t11-/m0/s1

HIDE SMILES / InChI

Molecular Formula C11H14ClN3O4S3
Molecular Weight 383.895
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Altizide, a thiazide diuretic, and aldosterone antagonist, in combination with spironolactone was marketed under brand name Aldactazine to treat patients with mild to moderate hypertension. In addition, Aldactazine was investigated for the treatment of congestive cardiac insufficiency.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

PubMed

Sample Use Guides

In Vivo Use Guide
Aldactazine ( 25 mg spironolactone and 15 mg altizide, 1/day)
Route of Administration: Oral
Substance Class Chemical
Record UNII
JI3ZO158IN
Record Status Validated (UNII)
Record Version